3.52
price up icon8.31%   0.27
after-market アフターアワーズ: 3.60 0.08 +2.27%
loading
前日終値:
$3.25
開ける:
$3.26
24時間の取引高:
120.91K
Relative Volume:
1.12
時価総額:
$20.38M
収益:
-
当期純損益:
$-16.76M
株価収益率:
-44.00
EPS:
-0.08
ネットキャッシュフロー:
$-132.97M
1週間 パフォーマンス:
+8.98%
1か月 パフォーマンス:
-19.08%
6か月 パフォーマンス:
-70.14%
1年 パフォーマンス:
-87.44%
1日の値動き範囲:
Value
$3.25
$3.56
1週間の範囲:
Value
$3.0011
$3.56
52週間の値動き範囲:
Value
$2.67
$33.90

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name
名前
X 4 Pharmaceuticals Inc
Name
セクター
Healthcare (1177)
Name
電話
857-529-8300
Name
住所
61 NORTH BEACON STREET, BOSTON, MA
Name
職員
143
Name
Twitter
@x4pharma
Name
次回の収益日
2025-03-25
Name
最新のSEC提出書
Name
XFOR's Discussions on Twitter

XFOR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
XFOR
X 4 Pharmaceuticals Inc
3.52 18.70M 0 -16.76M -132.97M -0.08
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.68 25.81B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.09 111.46B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 40.37M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.39 64.44B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
77.49 6.19B 0 -153.72M -103.81M -2.00

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-12-12 ダウングレード B. Riley Securities Buy → Neutral
2023-08-30 再開されました B. Riley Securities Buy
2022-12-22 開始されました Cantor Fitzgerald Overweight
2022-12-12 開始されました Piper Sandler Overweight
2019-12-23 開始されました Oppenheimer Outperform
2019-12-18 開始されました ROTH Capital Buy
2019-12-09 アップグレード Citigroup Neutral → Buy
2019-12-05 開始されました B. Riley FBR Buy
2019-06-07 開始されました Stifel Buy
2019-06-05 開始されました Cowen Outperform
すべてを表示

X 4 Pharmaceuticals Inc (XFOR) 最新ニュース

pulisher
May 28, 2025

Director Moos Walter H was granted 2,500 shares, increasing direct ownership by 24% to 12,722 units (SEC Form 4) - Quantisnow

May 28, 2025
pulisher
May 28, 2025

Director Hannah Alison L. was granted 2,500 shares, increasing direct ownership by 31% to 10,625 units (SEC Form 4) - Quantisnow

May 28, 2025
pulisher
May 28, 2025

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga

May 28, 2025
pulisher
May 27, 2025

SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow

May 27, 2025
pulisher
May 22, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Twinbeech Capital LP - MarketBeat

May 22, 2025
pulisher
May 22, 2025

Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace

May 22, 2025
pulisher
May 21, 2025

President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow

May 21, 2025
pulisher
May 19, 2025

President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4) - Quantisnow

May 19, 2025
pulisher
May 19, 2025

23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million - The New York Times

May 19, 2025
pulisher
May 19, 2025

Bankrupt 23andMe Expected to Be Purchased for $256M - People.com

May 19, 2025
pulisher
May 16, 2025

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - Quantisnow

May 16, 2025
pulisher
May 14, 2025

X4 Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Chronic Neutropenia Trial Data At The 30Th Annual Eha Congress - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data At the 30Th Annual Eha Congress - marketscreener.com

May 14, 2025
pulisher
May 13, 2025

Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance

May 13, 2025
pulisher
May 08, 2025

Fierce Biotech Layoff Tracker 2025: Insitro shrinks team by 22%; Shape ships out staff - Fierce Biotech

May 08, 2025
pulisher
May 07, 2025

Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 07, 2025
pulisher
May 07, 2025

What to Know About Eli Lilly’s Daily Pill for Weight Loss - The New York Times

May 07, 2025
pulisher
May 04, 2025

HC Wainwright Raises X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $7.00 - Defense World

May 04, 2025
pulisher
May 02, 2025

Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow

May 02, 2025
pulisher
May 02, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView

May 02, 2025
pulisher
May 02, 2025

X4 Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025
pulisher
May 02, 2025

XFOR: HC Wainwright Raises Price Target for X4 Pharmaceuticals | - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 - Quantisnow

May 02, 2025
pulisher
May 02, 2025

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 02, 2025
pulisher
May 02, 2025

X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ... - Yahoo Finance

May 02, 2025
pulisher
May 02, 2025

X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: - GuruFocus

May 02, 2025
pulisher
May 01, 2025

X4 Pharmaceuticals targets $1-2B U.S. market for mavorixafor in chronic neutropenia - MSN

May 01, 2025
pulisher
May 01, 2025

X4 Pharmaceuticals Q1 2025 slides: XOLREMDI launch drives revenue beat amid pipeline progress - Investing.com India

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: X4 Pharmaceuticals beats Q1 2025 EPS expectations - Investing.com Australia

May 01, 2025
pulisher
May 01, 2025

Earnings call transcript: X4 Pharmaceuticals beats Q1 2025 EPS expectations By Investing.com - Investing.com UK

May 01, 2025
pulisher
May 01, 2025

X4 Pharmaceuticals, Inc SEC 10-Q Report - TradingView

May 01, 2025
pulisher
May 01, 2025

X4 Pharmaceuticals (XFOR) Posts Strong Q1 Results with Notable C - GuruFocus

May 01, 2025
pulisher
May 01, 2025

X4 Pharmaceuticals: Q1 Earnings Snapshot - San Antonio Express-News

May 01, 2025
pulisher
May 01, 2025

X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings: EPS of $0.04 Bea - GuruFocus

May 01, 2025
pulisher
May 01, 2025

XFOR Q1 Revenue Surges to $28.8 Million, Spotlighting Significan - GuruFocus

May 01, 2025
pulisher
May 01, 2025

X4 Pharmaceuticals Full Enrollment On Track For 3Q Or 4Q 2025 And Top-Line Data In 2H 2026 - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire

May 01, 2025
pulisher
May 01, 2025

XFORX4 Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan

May 01, 2025
pulisher
Apr 30, 2025

Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025 - Insider Monkey

Apr 30, 2025
pulisher
Apr 30, 2025

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG - PR Newswire

Apr 30, 2025
pulisher
Apr 29, 2025

X Marks the Spot: Challenges for Therapeutic Target Engagement in DBS - Psychiatric Times

Apr 29, 2025
pulisher
Apr 28, 2025

Market Recap: X4 Pharmaceuticals Inc (XFOR)’s Positive Momentum, Closing at 0.19 - DWinneX

Apr 28, 2025
pulisher
Apr 28, 2025

The Potential Rise in the Price of X4 Pharmaceuticals Inc (XFOR) following insiders activity - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Top 3 Health Care Stocks That May Rocket Higher In April - Benzinga

Apr 28, 2025
pulisher
Apr 25, 2025

A look into X4 Pharmaceuticals Inc (XFOR)’s deeper side - Sete News

Apr 25, 2025
pulisher
Apr 25, 2025

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025 - marketscreener.com

Apr 25, 2025
pulisher
Apr 24, 2025

X4 Pharmaceuticals Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com

Apr 24, 2025
pulisher
Apr 24, 2025

X4 Pharmaceuticals To Enact 1-for-30 Reverse Stock Split, Effective April 28, 2025 - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

X4 Pharmaceuticals announces reverse stock split - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

X4 Pharmaceuticals Announces Reverse Stock Split - The Manila Times

Apr 24, 2025

X 4 Pharmaceuticals Inc (XFOR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.06
price up icon 0.95%
$31.31
price up icon 3.40%
$580.95
price up icon 0.82%
$292.90
price up icon 2.57%
$4.64
price up icon 6.67%
$77.49
price up icon 4.82%
大文字化:     |  ボリューム (24 時間):